After underperforming the overall market for the past few years, large-cap pharmaceutical stocks may now be positioned to outperform as the impact of tariffs on foreign products and services begins to take hold. Many investors who hold pharmaceutical stocks are breathing a sigh of relief, as many of the top companies in the sector are exempt from tariffs due to an executive order signed by the president.
We screened our 24/7 Wall St. pharmaceutical dividend stock universe, looking for the best large-cap companies that top banks and brokerage firms have current Buy ratings on and pay among the highest dividends in the sector. Four well-known names topped the list; all are safe options for nervous investors now.
This post appeared first on 24/7 Wall St.